ArticleFrontiers in neurology2025
Association between cardiometabolic index and stroke risk: insights from the CHARLS cohort study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of cardiometabolic index with prevalence of stroke, all-cause and cardiovascular mortality: a prospective cohort study.BMC public health · 2026Article
- Nonlinear relationship between incidence of new-onset stroke and plasma atherosclerotic index in middle-aged and older adults.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is a leading global health challenge, significantly burdening individuals and healthcare systems. The Cardiometabolic Index (CMI), a novel metric combining triglycerides, HDL cholesterol, and waist-to-height ratio, has shown promise in predicting metabolic diseases but its relationship with stroke risk is underexplored. Methods: This study analyzed data from 9,079 participants in the China Health and Retirement Longitudinal Study (CHARLS). Participants were stratified by CMI quintiles with the following ranges: Q1 (0.074-0.602), Q2 (0.602-0.935), Q3 (0.935-1.402), Q4 (1.402-2.327), and Q5 (2.327-74.326). Stroke incidence over a 7.8-year follow-up period was assessed. Cox proportional hazard models and restricted cubic spline regression were used to evaluate the association between baseline CMI and stroke risk, adjusting for confounders. Results: Higher CMI levels were significantly associated with increased stroke risk, with a 21% higher risk per 1-unit increase in CMI after adjustment (HR: 1.21, 95% CI: 1.11-1.32). Stroke incidence showed a dose-response relationship, particularly above a CMI threshold of 1.6. Conclusion: Elevated CMI is a strong independent predictor of stroke risk, highlighting its potential as a clinical tool for early risk stratification and prevention. Further large-scale studies are needed to validate its utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.